Objective: We used a new graphical ordinal logit method (GOLDminer) to assess a single cardiac troponin T (cTnT) analysis at the time of admission (first generation monoclonal; Roche BMC Corp., Indianapolis, Indiana), the character ofchest pain, and electrocardiographic (ECG)findings in predicting the likelihood of acute myocardial infarction (AMI) in patients presenting with suspected myocardial ischemia. Thefinal diagnosis ofAMI was based on serial ECGfindings and evolution of CKMB isoenzyme levels in conjunction with clinicalfindings.
INTRODUCTION
The diagnosis of acute myocardial infarction (AMI)b is problematic for many patients who present with equivocal symptoms or electrocardiographic (ECG) findings. Chest pain is associated with an overtriage of patients to the coronary care unit since less than one-third of chest pain patients demonstrate creatine kinase isoenzyme MB (CKMB) changes [1] [2] [3] [4] . Additionally, in nearly 10 percent of patients, the diagnosis of AMI cannot be definitively confirmed or excluded [5] .
Although serial measurement of blood CKMB is a widely used biochemical marker in the diagnosis of AMI [6, 7] , CKMB levels typically are not increased until nine hours after the onset of chest pain. Given the late rise of CKMB, the CKMB mass assay has less than 70 percent sensitivity in the diagnosis of AMI at the time of presentation to the emergency department [8] . Newer biochemical markers have been utilized to aid in the diagnosis of AMI, including cTnT, which rises to abnormal levels in serum within four to sixhours after the onset of myocardial damage, remains elevated for a week or longer, and is associated with a significant likelihood of cardiac events [9] [10] [11] [12] [13] [14] . Despite conflicting views about which troponin is best to use, there is now a recommendation for incorporating them in the WHO guidelines for AMI diagnosis, with special interest in their value for risk stratifying patients with unstable angina [15] . There has also been a recommendation to integrate the troponins with the Goldman algorithm [16, 17] . We specifically chose troponin T to study because there was already a substantial literature about the sensitivity of the assay and its value in identifying a subset of unstable angina patients with the same risk as AMI. The value of the cardiac marker was not proved for emergency room decisions based on an initial blood sample taken at the time patients present with chest pain. We carried out this study by blinding the physicians to the troponin results and proposed that the laboratory can incorporate this method in a clinical pathway for decisions about the disposition of patients presenting with clinical features suggestive of AMI [18] .
We describe a novel method for interpreting the clinical, electrocardiographic, and the laboratory features of patients presenting with suggested myocardial infarction. The result is not a binary response, but rather a graded relationship that is most useful for fitting the data to observed outcomes and for predicting expected responses. The decision-making method described can reduce medical treatment failure rates, lower the cost of managing chest pain patients, and improve the delivery of health care.
We Scaling the data and partitioning the population into pattern classes: The data were used to classify the patients whose diagnoses were known (AMI, unstable angina, and nonischemic chest pain). These data were used in a classifying matrix separating the population into two classes, AMI or not, based on cTnT less than 0.1 ng/ml, or equal to or greater than 0.1 ng/ml. The other clinical and laboratory features were scaled: initial CKMB was scaled to 0 if less than 17 U/I, and 1 if equal to or above 17 U/I [21] ; and the CKMB evolution was 0 if negative, and 1 if there was typical evolution of AMI. The ECG data were scaled to: 3, ST segment elevation; 2, Q waves; 1, ST segment depression/T wave inversion; 0, normal; -1, other. The characteristics of the chest pain were scaled to: 2, typical; 1, atypical; 0, other presenting feature. cTnT was scaled to: -1, <0.05; 0,0.05 to 0.099; 1,0.1 to 0.2; 2,0.2 to 0.5; 3, 0.5 to 1; 4, > 1 ng/ml. Justification of the universal regression model: The "universal" probability model overcomes errors that arise from using linear regression for ordered variables. The scaled data form a cross-table that is used in the universal regression We review the steps required to get to Figure 1 . Each cell has an observed and expected frequency. The probabilities of each cell are obtained by dividing the expected (or observed) frequency by the total frequency for the column. The probabilities add to 1. The odds-ratio is calculated by comparing the ratio of the Y-reference odds to the baseline or X-reference odds. The odds are obtained by taking the ratio of the frequency count for an outcome category to that of the outcome reference. In this case the outcome reference is the column "normal ECG." Consider the example of "cTnT < 0.05," and "cTnT > 1 with ST elevation" as the outcome and "normal ECG" as the reference. The expected odds for "cTnT < 0.05" or for "cTnT > 1 with ST elevation" are 3.46/3.47 (= 1) and 13.19/3.47 (= 3.80) using the axis-reference of 3.47. The expected odds for "normal ECG" versus "ST elevation with cTnT < 0.05" are 53.09/51.92 (= 1.02) and 3.46/51.92 (= 0.07) using the axis-reference of 51.92. The axis-reference frequencies are hidden from view in this presentation. The expected odds for the cells are calculated before calculating the odds-ratios. The Yreference may be displayed on the right for each row, and the X-reference may be displayed at the bottom of each column, but the variables may also be reversed, particularly in this example. The important point is that calculation of odds prior to calculating the odds-ratio requires that the entire Y-reference be converted to a value of 1 by dividing all the cell frequencies by the reference frequency. The odds-ratio is next calculated by converting the X-reference to a baseline of 1. Table 2 is the calculated odds that are used for the odds-ratios shown in Figure 1 using a cTnT reference of 0.1 ng/ml. The reference odds listed in the last row of each column coincides with the odds at cTnT < 0.1 (0.05 to 0.1). There is a reference odds for each column, or ECG category. The odds-ratio is calculated for any cTnT value in an ECG category with the odds-ratio for cTnT < 0.1 as 1 by dividing the odds by the reference odds. 
DISCUSSION
Our study validates the diagnostic utility of cTnT values at the time of presentation and is unique in several ways. We studied the entire spectrum of patients presenting to the emergency department with a suspicion of AMI and not just patients with chest discomfort. Secondly, the cTnT results and the decision-making process were separated. This had implications for test validation. The test cutoff was determined by a process independent of the clinical decisions used in patient care. We then evaluated the role of serum cTnT in the diagnosis of AMI in relationship to the other features in the diagnosis of AMI. We argue that cTnT has great value for relieving uncertainty when the clinical features are not definitive for excluding AMI. The universal regression model clarifies the underlying relationship between the serum markers, clinical features, and outcomes. This type of modeling allows us to form a classification with features that can be displayed in a truth table. Instead of the individual tests or symptoms, the combinations of features resolve uncertainty, just as as the pixels on a screen give resolution in picture definition.
The GOLDminerTM method unmasks the underlying autocorrelation between cTnT and ECG findings in the data. We use the GOLDminerTM to examine the probability characteristics of the feature combinations as more and more uncertainty is relieved. This approach is considerably more satisfying than other models currently in use and may have future implications for medical practice and decision making. This is especially important in the case where there are equivocal clinical and ECG findings. The diagnostic efficiency of cTnT values at the time of presentation coupled with clinical and electrocardiographic findings allows rapid decision making and patient triage resulting in potential enormous healthcare savings.
